Targeted Therapy Helps High-Risk Pediatric Hodgkin’s Lymphoma
The targeted therapy brentuximab vedotin has significantly reduced relapse rates among children with high-risk Hodgkin’s lymphoma.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
